Skip to main content
LLY
NYSE Life Sciences

Foundayo Hits Phase 3 Sleep Apnea Goal; Lilly Eyes FDA Filing by End-2026

Tom Rudovsky · Reported by Wiseek News
More coverage: Pharmaceutical Stocks · Healthcare
Sentiment info
Positive
Importance info
7
Price
$1,411.12
Mkt Cap
$1.328T
52W Low
$850.51
52W High
$1,453
52W Position info
66% above low
Off High info
2.9% below high
Rel. Volume info
1.6× avg
Market data snapshot near publication time

LLY sits 66% above its 52-week low of $850.51.

Summary

Lilly's oral GLP-1 Foundayo met the primary endpoint in a Phase 3 sleep apnea trial, with patients losing about 11% of body weight after 52 weeks. Lilly plans to file for U.S. approval by end-2026, adding a new indication to a drug already backed by the ACHIEVE-4 cardiovascular data reported in late September. Separately, Lilly and Hims & Hers will sell Zepbound and Foundayo to eligible patients at self-pay prices starting at $299 and $149 a month, with Hims agreeing not to sell compounded copies — a direct cash-pay channel that sidesteps insurer coverage friction. Jefferies kept its Buy rating and lifted its target to $1,700 from $1,610, citing overseas GLP-1 demand; the stock rose 3.4% to $1,400.04 Monday and sits near its 52-week high. The sleep apnea filing timeline is the concrete milestone to track.

At the time of this announcement, LLY was trading at $1,411.12 on NYSE in the Life Sciences sector, with a market capitalization of approximately $1.3T. The 52-week trading range was $850.51 to $1,453.00. This news item was assessed with positive market sentiment and an importance score of 7 out of 10. Source: Wiseek News.


Price Chart

Share this article

Copied!

LLY - Latest Insights

LLY
Nov 09, 2026, 10:23 AM EST
Source: Dow Jones Newswires
Importance Score:
8
Price at Filing: $1,394.15
Real-time Price: $1,411.12 info
Change: +$16.97 (+1%) info
Market Cap: $1.328T info
LLY
Nov 06, 2026, 6:45 AM EST
Source: Reuters
Importance Score:
7
Price at Filing: $1,346.00
Real-time Price: $1,411.12 info
Change: +$65.12 (+5%) info
Market Cap: $1.328T info
LLY
Nov 04, 2026, 1:53 AM EST
Source: Reuters
Importance Score:
7
Price at Filing: $1,416.54
Real-time Price: $1,411.12 info
Change: -$5.42 (-0.38%) info
Market Cap: $1.328T info
LLY
Oct 29, 2026, 3:21 PM EDT
Source: Dow Jones Newswires
Importance Score:
7
Price at Filing: $1,368.10
Real-time Price: $1,411.12 info
Change: +$43.02 (+3%) info
Market Cap: $1.328T info
LLY
Oct 29, 2026, 12:08 PM EDT
Source: Dow Jones Newswires
Importance Score:
9
Price at Filing: $1,370.30
Real-time Price: $1,411.12 info
Change: +$40.82 (+3%) info
Market Cap: $1.328T info